Neuroblastoma Clinical Trials

39 studies are recruiting for neuroblastoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

   3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate…

   Stage

   Phase 1

   Ages

   Up to 21

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT04897321 on ClinicalTrials.gov

2. Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

   The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.

   Stage

   Phase 1

   Ages

   2 to 30

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT06500819 on ClinicalTrials.gov

3. Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

   Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this stu…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   New York Medical College, Valhalla, New York

   Run by

   New York Medical College

   See if you can join NCT04308330 on ClinicalTrials.gov

4. Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

   The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by …

   Stage

   Phase 1

   Ages

   1 and older

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

   Locations

   2 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT03721068 on ClinicalTrials.gov

5. Neuroblastoma Biology Study

   Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and n…

   Stage

   Not phased

   Ages

   0 to 99

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   17 in total

   Run by

   New Approaches to Neuroblastoma Therapy Consortium

   See if you can join NCT01587300 on ClinicalTrials.gov

6. Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

   The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered…

   Stage

   Not phased

   Ages

   Up to 17

   Site

   Connecticut Children's Medical Center, Hartford, Connecticut

   Locations

   6 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06831552 on ClinicalTrials.gov

7. Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

   The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in children with refractory or recurrent neuroblastoma or refractory/ re…

   Stage

   Phase 1

   Ages

   1 and older

   Site

   Children's Healthcare of Atlanta, Atlanta, Georgia

   Run by

   Emory University

   See if you can join NCT05400603 on ClinicalTrials.gov

8. Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

   This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideall…

   Stage

   Phase 2

   Ages

   Up to 30

   Site

   Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT02605421 on ClinicalTrials.gov

9. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

   This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

   Stage

   Phase 1

   Ages

   0 to 21

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT02508038 on ClinicalTrials.gov

10. Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

    The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and …

    Stage

    Not phased

    Ages

    Any age

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT00588068 on ClinicalTrials.gov

11. GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

    This research study combines two different ways of fighting cancer: antibodies and Natural Killer T cells (NKT). Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special white blood cells that can kill other…

    Stage

    Phase 1

    Ages

    1 to 21

    Site

    Texas Children's Hospital, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT03294954 on ClinicalTrials.gov

12. A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

    This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have…

    Stage

    Phase 2

    Ages

    1 to 40

    Site

    Children's Hospital of Alabama/UAB, Birmingham, Alabama

    Locations

    6 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05135975 on ClinicalTrials.gov

13. MCT for the Harvard/UCSF ROBIN Center

    The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that unde…

    Stage

    Not phased

    Ages

    Any age

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06000787 on ClinicalTrials.gov

14. International PPB/DICER1 Registry

    Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treatin…

    Stage

    Not phased

    Ages

    Up to 100

    Site

    Children's Minnesota, Minneapolis, Minnesota

    Run by

    Children's Hospitals and Clinics of Minnesota

    See if you can join NCT03382158 on ClinicalTrials.gov